Background. Oxidative stress, inflammation and cardiac apoptosis were closely involved in doxorubicin (DOX)-induced cardiac injury. Piperine has been reported to suppress inflammatory response and pyroptosis in macrophages. However, whether piperine could protect the mice against DOX-related cardiac injury remain unclear. is study aimed to investigate whether piperine inhibited DOX-related cardiac injury in mice. Methods. To induce DOX-related acute cardiac injury, mice in DOX group were intraperitoneally injected with a single dose of DOX (15 mg/kg). To investigate the protective effects of piperine, mice were orally treated for 3 weeks with piperine (50 mg/kg, 18:00 every day) beginning two weeks before DOX injection. Results. Piperine treatment significantly alleviated DOX-induced cardiac injury, and improved cardiac function. Piperine also reduced myocardial oxidative stress, inflammation and apoptosis in mice with DOX injection. Piperine also improved cell viability, and reduced oxidative damage and inflammatory factors in cardiomyocytes. We also found that piperine activated peroxisome proliferator-activated receptor-γ (PPAR-γ), and the protective effects of piperine were abolished by the treatment of the PPAR-γ antagonist in vivo and in vitro. Conclusions. Piperine could suppress DOX-related cardiac injury via activation of PPAR-γ in mice.
Introduction
A medical survey conducted by National Health and Nutrition Examination, which included 1807 cancer survivors, showed that 33% died of heart diseases [1] . As a representative drug of anthracycline, doxorubicin (DOX) is one of the major culprits in chemotherapy-induced cardiotoxicity, which could lead to irreversible degenerative cardiomyopathy and heart failure [2] . Because of the tremendous burden of managing DOX-induced cardiotoxicity, rapid discovery of effective treatments would be of great significance. e pathogenesis of DOX-induced cardiotoxicity are not completely understood, but increasing evidence suggests that oxidative stress, inflammation accumulation and cardiac apoptosis are closely involved [3, 4] . We previously found suppressing apoptosis prevented DOX-induced cardiomyopathy in mice [5] . It has been reported that activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) by pioglitazone ameliorated cardiac oxidative stress and inflammation in rats with metabolic syndrome [6] . PPAR-γ activation inhibited septic-related cardiac dysfunction via attenuation of apoptosis in rats [7] . Moreover, PPAR-γ mRNA and protein expression were significantly decreased in mice with DOX treatment [8] , and upregulation of PPAR-γ antagonized DOX-induced cardiotoxicity in cardiac cells [9] . e findings highlighted the possibility of developing therapeutic strategies targeting PPAR-γ to treat DOX-related cardiac injury.
Piperine is the bioactive alkaloid ingredient of black pepper and long pepper [10] . Piperine presented a diverse of biological activities including immune modulation, antidepressive disorders and mitigating obesity and diabetes [11] . It is noteworthy that piperine could reduce the production of type I interferon and antagonize lipopolysaccharide-induced inflammatory responses [12] . Piperine also significantly inhibited the release of inflammatory factors and pyroptosis in lipopolysaccharide-primed macrophages by activating AMPactivated protein kinase [13] . e data in our lab demonstrated that piperine was a moderate agonist of PPAR-γ and could attenuate pathological cardiac fibrosis in mice [14] . However, whether piperine could protect the mice against DOX-related cardiac injury remain unclear. Here, we have shown that piperine attenuated cardiac injury and improved cardiac function in DOX-treated mice via activation of PPAR-γ.
Materials and Methods
2.1. Reagents. Piperine (≥97% purity) was obtained from Shanghai Winherb Medical Science Co. (Shanghai, China). DOX (D1515, purity ≥98%) and GW9662 (M6191, purity ≥98%) were purchased from Sigma-Aldrich (St. Louis, MO, USA). e following first antibodies were purchased from Abcam (Cambridge, UK): anti-nuclear factor κB (NF-κB, ab16502, 1 : 1000), anti-GAPDH (ab181602, 1 : 1000), antiproliferating cell nuclear antigen (PCNA, ab92552, 1 : 1000), anti-tumor necrosis factor-α (TNF-α, ab6671, 1 : 1000), antinuclear factor erythroid-2-related factor 2 (Nrf2, ab76026, 1 : 1000), anti-Bcl-2 (ab185002, 1 : 1000), cleaved-caspase3 (ab2302, 1 : 1000). e N-terminal pro brain natriuretic peptide (NT-proBNP) detection kit was provided by My BioSource (CA, USA). Cardiac troponin I (cTnI) detection kit was purchased from Life Diagnostics, Inc (West Chester, PA).
Animals and Treatments.
All animal experimental procedures were in accordance with the Guidelines for the Animal Use Committees of our hospital and our institute. All the C57BL/6 mice (Age: 8-10 weeks, 24-26 g) were divided into four groups (푛 = 12 each group): normal saline (NS) + vehicle, NS + piperine, DOX + vehicle and DOX + piperine, by a random number table. e dose of piperine was selected according to our previous study [14] . To investigate the protective effects of piperine, mice were orally treated for 3 weeks with piperine (50 mg/kg, 18:00 every day), which was diluted in DMSO (0.1% v/v), beginning two weeks before DOX injection. Mice in the vehicle group were given the same volume of DMSO (0.1% v/v). To induce DOX-related acute cardiac injury, mice in DOX group were intraperitoneally injected with a single dose of DOX (15 mg/kg) and the control animals were subjected to equal volume of NS. One week post DOX injection, invasive hemodynamic monitoring was performed and a er that these mice were killed with an overdose of sodium pentobarbital and the hearts were collected for further detection. To verify the hypothesis that piperine exerted its cardioprotection via activating PPAR-γ, mice were treated with a PPAR-γ inhibitor (GW9662, 0.35 mg/kg per day in drinking water) for 2 weeks beginning one week before DOX injection as previously described [15] .
HE Staining.
e heart were fixed with neutral formalin and then processed by standard histological protocol and stained with haematoxylin and eosin (HE). e sections were observed to find pathological alterations caused by DOX.
2.4.
Hemodynamics. Invasive hemodynamic monitoring was performed according to our previous studies [14, 16, 17] . Le ventricular performance was analyzed in anesthetized mice (isoflurane 1.5% v/v) by using 1-F microtip pressure-volume catheter, which was connected to a Millar Pressure-Volume System (MPVS-400; Millar Instruments) and the data were analyzed using PVAN data analysis so ware.
Western Immunoblot.
Protein was extracted from the heart samples using RIPA lysis buffer containing protease inhibitor and phosphatase inhibitor cocktail. Proteins were fractionated on SDS-PAGE and then transferred onto polyvinylidene difluoride (PVDF) membrane (Invitrogen) [18, 19] . A er incubating with the first antibodies at 4°C overnight and the second antibodies at room temperature for one hour, these membranes were scanned with enhanced chemiluminescence reagent and visualized using the BIO-RAD ChemiDoc Touch Imaging System (BIO-RAD, Hercules, CA, USA). GAPDH was used as the internal control. e nuclear protein was prepared according to the manufacturer's instructions ( ermo Fisher Scientific, MD, USA) and PCNA was used as internal control.
Quantitative Real-Time PCR.
e frozen heart tissues or cell lysates were lysed using TRIzol reagent (Invitrogen Life Technologies, USA) to extract the total RNA. A er that, total RNA was reversely transcribed to cDNA using Transcriptor First Strand cDNA Synthesis Kit (Roche, USA). Real-time PCR was performed using LightCycler 480 SYBR Green Master Mix (Roche Diagnostics). e expression levels of the target genes were normalized to that of GAPDH.
Terminal Deoxynucleotidyl Transferase-Meditated dUTP
Nick-End Labeling (TUNEL) Staining. Fresh heart samples were cut into sections and fixed in paraformaldehyde (4%, ml/ ml) at room temperature. TUNEL detection was performed using ApopTag Peroxidase In Situ Apoptosis Detection Kit (Chemicon, CA, USA). For each animal, five sections were selected to count apoptotic nuclei. For each slide 8 fields were randomly chosen.
Antioxidant Assay, Determination of cTnI, NT-ProBNP, Lactate Dehydrogenase and Caspase3 Activity.
e heart tissue was homogenized and the supernatant fraction was collected to detect activities antioxidant enzyme. e levels of malondialdehyde (MDA) and 3-nitrotyrosine (3-NT), and the activity of total superoxide dismutase (SOD) were assayed according to the manufacturer's protocols.
MDA assay kit (No: A003-1-2) and SOD activity assay kit (No: A001-3-2) were obtained from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). 3-NT detection kit was provided by Abcam (No: ab116691).
ree days a er DOX injection, blood was collected from the retro-orbital plexus to detect cTnI and NT-pro BNP to reflect cardiac injury using the commercial kits.
A er treatment, fresh hearts or cells were homogenized to detect lactate dehydrogenase (LDH) release and the activity of caspase3. e level of LDH and caspase3 activity were assayed using kits from Nanjing Jiancheng Bioengineering Institute according to the manufacturer's protocols.
Cell Culture and Treatment.
e H9c2 cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). Cells were routinely seeded in DMEM (Gibco, NY, USA) containing 10% fetal bovine serum (Gibco), penicillin (100 U/ml) and streptomycin (100 U/ml) (Gibco). Only cells below passage 10 were used in our study. H9c2 cells were treated with DOX (1 μmol/L) or PBS for 24 h to mimic DOX-related cardiac injury in vivo. Meanwhile, piperine (20 μmol/l) dissolved in DMSO (0.1% v/v) was given [14] . For PPAR-γ inhibition, H9c2 cells were given a specific PPAR-γ antagonist (GW9662, 10 μmol/l) for 48 h beginning from 24 h before piperine and DOX treatment [14] . To evaluate PPAR-γ transactivation a er piperine treatment, H9c2 cells were electrotransfected with Ppre-luc (0.04 μg) and Ppar-γ plasmid (0.4 μg) using Neon® Transfection System (pulse voltage: 1750 V, pulse width: 25 ms) [14] . H9c2 cells were harvested 48 h later and luciferase assays performed using a Single-Mode SpectraMax® Microplate Reader to detect the transactivation of PPAR-γ. Cell viability a er piperine treatment was determined using the CCK-8 kit according to the manufacturer's instructions.
Statistical Analysis.
All the data are expressed as mean ± SD. Differences were analysed using one-way analysis of variance (ANOVA) and post hoc analysis was performed with the Tukey test in SPSS so ware package. Statistical significance was accepted at a value of 푃 < 0.05.
Results

Piperine Attenuated Cardiac Injury in Mice with DOX Injection.
e mice subjected to DOX injection had decreased body weight and heart weight/tibia length (HW/TL). However, these pathological alterations in DOX-treated mice were significantly reduced a er piperine treatment (Figures 1(a) and 1(b)). Plasma levels of cTnI is a best-known marker of cardiac injury. DOX injection resulted in a marked increase in the level of cTnI, and piperine treatment significantly decreased this elevation in DOX-injected mice (Figure 1(c) ). e level of NT-proBNP was increased in DOX group, and piperine treatment decreased the increased level of NT-proBNP ( Figure 1(d) ).
To further evaluate the effect of piperine on DOX-induced cardiac injury, HE staining was performed. Piperine largely reduced interruption of myofibrillar in DOX-treated mice (Figure 1(e) ).
Piperine Improved Cardiac Function in Mice Subjected
to DOX Injection. DOX injection decreased heart rate in mice, this toxic effect was attenuated a er piperine treatment (Figure 2(a) ). e mice subjected to DOX injection developed deteriorated cardiac function, as indicated by the decrease in ejection fraction (EF), dP/dt max and dP/dt min ( had higher levels of TNF-α, interleukin (IL)-6, and monocyte chemoattractant protein 1 (MCP-1) compared with mice with NS injection (Figures 3(a)-3(c) ). ese increased inflammatory factors were attenuated a er piperine treatment (Figures 3(a)-3(c) ). DOX stimulated nuclear NF-κB accumu-
Piperine Efficiently Blocked DOX-Induced Inflammation
Accumulation in Mice. Inflammation is one of major features of acute cardiotoxicity caused by DOX injection in mice [20] . erefore, we detected the effect of piperine on myocardial inflammation in DOX-treated mice. DOX-treated mice 
Piperine Inhibited DOX-Related Cardiomyocytes Injury In
Vitro via Activating PPAR-γ Receptor. To further investigate the effect of piperine on DOX-induced damage, H9c2 cardiomyocytes were used. Dox significantly reduced the cell viability of cardiomyocytes, and this effect was attenuated by piperine treatment (Figure 6(a) ). Piperine also reduced MDA content and increased SOD activity in DOX-treated cells (Figures 6(b) and 6(c)). e increased mRNA level of TNF-α and IL-6 in DOX-treated cells were also suppressed by piperine in vitro (Figures 6(d) and 6(e))). Piperine also reduced caspase3 mRNA and cleaved-caspase3 protein level in DOX-treated cells (Figures 6(f) and 6(g)). Consistent with our study [14] , we found that piperine (20 μmol/l) could transactivate PPAR-γ and also exhibited a 2.5-fold increase in PPAR-γ gene in H9c2 even at baseline (Figure 6(h) ). DOX decreased the transactivation and the mRNA expression of PPAR-γ in vitro, and piperine treatment largely inhibited this pathological alterations in DOX-treated cells (Figure 6(i) ). Piperine increased PPARγ protein expression at baseline, and also restored PPAR-γ protein expression in DOX-treated cells (Figure 6(j) ). GW9662 pretreatment, an irreversible antagonist of PPAR-γ, completely lation in mice; this effect was inhibited by piperine treatment (Figure 3(d) ). Further detection of TNF-α protein expression also revealed that piperine reduced cardiac TNF-α expression in mice from DOX group (Figure 3(e) ).
Piperine Attenuated DOX-Induced Cardiac Oxidative Stress in Mice.
To determine whether piperine could inhibit DOXinduced oxidative damage in mice, we compared the levels of MDA and 3-NT, and the total activity of SOD in mice. Results of these studies showed that piperine could significantly reduce the levels of MDA and 3-NT, and upregulated SOD activity in mice (Figures 4(a)-4(c) ). Further detection also revealed that piperine restored Nrf2 expression to the normal level in mice with DOX injection (Figure 4(d) ).
Piperine Inhibited Cardiomyocytes Apoptosis in response
to DOX. Next, we further evaluated apoptosis using the TUNEL assay. We observed a reduction in the TUNEL + cells in mice from DOX + piperine group compared with that of mice from DOX + vehicle group (Figure 5(a) ).Piperine also downregulated the mRNA levels of Bax (pro-apoptotic gene) and caspase 3 but upregulated the mRNA level of Bcl-2 (antiapoptotic gene) in DOX-treated mice (Figures 5(b)-5(d) ). Further detection revealed that piperine also upregulated the treated with a PPAR-γ inhibitor (GW9662, 0.35 mg/kg per day in drinking water). e data in our study demonstrated that there was no difference in EF, TNF-α, MDA content and caspase3 activity between DOX+vehicle+GW9662 and DOX+piperine+GW9662 group (Figures 7(a)-7(d) ).
blocked the protective effects of piperine on cell viability and LDH release in vitro (Figures 6(k) and 6(l)).
Piperine Lost Cardiac Protection in Mice with GW9662
Treatment. To further confirm the role of PPAR-γ, mice were (l) 9 PPAR Research accumulation, thus promoting the pathogenesis of DOXrelated cardiac injury. As expected, we also found that piperine decreased myocardial inflammatory factors and nuclear NF-κB accumulation in mice, which was in line with a previous study that piperine inhibited lipopolysaccharide-induced inflammatory responses [12] .
Death is the ultimate outcome of injured cells, and cell death is a direct cause of DOX-induced cardiac dysfunction. Accumulating evidence indicated that DOX caused apoptotic cell death among both endothelial cells and cardiomyocytes [5, 26] . In our study, we also found that piperine attenuated DOX-induced cardiac apoptosis in mice and improved cell viability in vitro. e inhibition of cell loss by piperine, at least partly, contributed to the protection of piperine against DOXrelated injury.
It has been reported that activation of PPAR-γ could ameliorate palmitate-induced apoptosis in skeletal muscle cells [27] . DOX treatment significantly decreased the level of PPAR-γ [28] . ese findings suggested that a PPAR-γ agonist might protect the mice from DOX-related cardiac injury. Consistent with our previous study [14] , we found that piperine transactivated PPAR-γ and increased PPAR-γ mRNA in DOX-treated cells. Moreover, piperine could reduce
Discussion
Our central finding is that piperine protected against DOXinduced cardiac injury and improved cardiac function in mice. Piperine also attenuated myocardial oxidative stress, inflammation and apoptosis in DOX-treated mice. We also found that piperine activated PPAR-γ receptors and PPAR-γ receptors inhibition could offset piperine-mediated protection in mice.
Accumulating evidence demonstrated that increased in oxidative stress and lipid peroxidation, along with reductions of antioxidants played key roles in the process of DOX-induced injury [21] . e heart samples are vulnerable to oxidative damage induced by DOX for the reason that there are a lot of mitochondrial content and relatively low levels of antioxidant enzymes [22] . Acute DOX injection significantly increased the levels of reactive oxygen species (ROS) and MDA level [23] . DOX also suppressed a variety of antioxidants, which further promoted oxidative stress in response to DOX treatment [24] . Here, we found that piperine markedly reduced MDA and 3-NT content, and improved SOD activity. We also found that piperine restored the level of Nrf2 in DOX-treated mice, and this finding was consistent with a previous study [25] . Accumulation of ROS in the hearts upregulated cardiac TNF-α DOX-related cardiac injury, as reflected by decreased cTnI and NT-proBNP, and improved cardiac function in mice. Moreover, these protective effects were blocked by GW9662 pretreatment, which is an irreversible antagonist of PPAR-γ, implying piperine exerted its cardioprotection via activating PPAR-γ. It has been accepted that rosiglitazone and pioglitazone are agonists of PPAR-γ. However, their therapeutic use is limited by the potential cardiovascular risks including weight gain, which was largely caused by the high affinity of thiazolidinedione for PPAR-γ and the resultant PPAR-γ overactivation [29, 30] . In our previous study, we found the ability that piperine activated PPAR-γ pathway was less effective than pioglitazone [14] , suggesting that that piperine partially activate PPAR-γ. Moreover, piperine did not affect body weight in mice without DOX injection, though piperine increased body weight in DOX-treated mice. In addition, it has been reported that piperine suppressed the growth of human melanoma cells in vivo and in vitro [31] , implying that piperine might not compromise therapeutic DOX levels or promote tumor growth.
In conclusion, our study demonstrated that piperine protected against DOX-induced by cardiac injury via activating PPAR-γ pathway in mice. Our study provided experimental evidence for the clinical use of piperine in the treatment of DOX-related cardiac injury.
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